Piper Sandler lowered the firm’s price target on BioMarin to $125 from $128 and keeps an Overweight rating on the shares following the "solid" Q1 results. The firm says poor messaging regarding Roctavian "continues to cloud an otherwise compelling growth story." However, BioMarin’s fundamentals remain intact the stock should be bought on any weakness, the analyst tells investors in a research note.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on BMRN:
- BioMarin price target lowered to $120 from $125 at Guggenheim
- BioMarin price target raised to $127 from $112 at Baird
- BioMarin Announces Record Breaking First Quarter 2023 Results, Including 15% Year-over-year Growth of Total Revenues
- BioMarin sees FY23 adjusted EPS $1.80-$2.05, consensus 95c
- BioMarin reports Q1 adjusted EPS 60c, consensus 18c
